卵巢癌骨转移患者的血清β-CTx、N-MID和β-Crosslaps表达水平及临床意义  

Expression of serum β-CTx, N-MID and β-Crosslaps in patients with ovarian cancer with bone metastasis and the clinical significarice

作　　者：陈雪[1] 李秋菊[1] 杨利丽[1] 李俊峰[2] CHEN Xue;LI Qiuju;YANG Lili;LI Junfeng(Department of Orthopedics,the Second Hospital of Jilin University,Changchun,130041,Jilin,China;Department of Laboratory,the Second Hospital of Jilin University,Changchun,130041,Jilin,China)

机构地区：[1]吉林大学第二医院骨科,长春1300410 [2]吉林大学第二医院检验科,长春1300410

出　　处：《癌症进展》2019年第2期207-209,230,共4页Oncology Progress

摘　　要：目的探讨卵巢癌骨转移患者的血清β-Ⅰ型胶原羧基端肽(β-CTx)、N-端骨钙素(N-MID)和β-胶原特殊序列(β-Crosslaps)表达水平及临床意义。方法选取64例卵巢癌骨转移患者(卵巢癌骨转移组)、64例未发生骨转移的卵巢癌患者(卵巢癌无骨转移组)和64例健康体检者(健康组),比较3组研究对象的血清β-CTx、N-MID及β-Crosslaps水平。根据骨转移病灶数目将卵巢癌骨转移患者分为4组,骨转移病灶≤6个为A组,6个﹤骨转移病灶≤20个为B组,20个<骨转移病灶≤30个为C组,骨转移病灶>30个为D组。对卵巢癌骨转移患者随访1年,根据死亡情况分为死亡组和未死亡组。分析不同骨转移病灶数目、不同预后情况的卵巢癌骨转移患者的血清β-CTx、N-MID及β-Crosslaps水平。结果卵巢癌骨转移组患者的血清β-CTx、N-MID及β-Crosslaps水平均高于卵巢癌无骨转移组和健康组(P﹤0.05)。A组、B组、C组、D组卵巢癌骨转移患者的血清β-CTx、N-MID及β-Cross-laps水平比较,差异均有统计学意义(P﹤0.01);随着骨转移病灶数目的增加,患者的血清β-CTx、N-MID及β-Crosslaps水平均逐渐升高,4组间两两比较,差异均有统计学意义(P﹤0.05)。未死亡组患者入院时的血清β-CTx、N-MID及β-Crosslaps水平均明显低于死亡组(P﹤0.01)。结论卵巢癌发生骨转移时,血清骨代谢标志物β-CTx、N-MID及β-Crosslaps水平均发生改变,其对卵巢癌骨转移的诊断、病情评估以及预后预测具有重要价值。Objective To study the expression ofβtypeⅠcollagen carboxyl terminal peptide(β-CTx),N-terminal osteocalcin(N-MID),and special sequence ofβcollagen(β-Crosslaps)in patients with ovarian cancer and bone metastases,and to investigate its clinical significance.Method The clinical data of 64 patients with bone metastases derived from ovarian cancer were included in the study as bone metastasis group,another 64 patients with ovarian cancer but without bone metastasis and 64 healthy subjects were recruited as non-bone metastasis group and control group,respectively,the level ofβ-CTx,N-MID,andβ-Crosslaps in the three groups were analyzed.In bone metastasis group,patients were further stratified as 4 subgroups,group A was with metastasis sites≤6,group B with 7-20,group C with 21-30,and group D with >30 sites.All patients with bone metastasis were followed up for 1 year,and death cases were investigated.The serumβ-CTx,N-MID,andβ-Crosslaps level in patients of different bone metastases sites group and different prognosis were analyzed.Result The serum levels ofβ-CTx,N-MID andβ-Crosslaps in patients with ovarian cancer and bone metastasis were significantly lower than those in patients without metastasis and healthy controls(P<0.05);patients in group A,B,C,and D had varying serum level ofβ-CTx,N-MID,andβ-Crosslaps(P<0.01);besides,the serum level ofβ-CTx,N-MID,andβ-Crosslaps gradually elevated as the number of bone metastatic sites increased,and significant differences were noted among the 4 subgroups(P<0.05).The serum level ofβ-CTx,N-MID,andβ-Crosslaps on admission in patients who were alive were significantly lower than those in death cases(P<0.01).Conclusion When bone metastases occur in ovarian cancer,there will be significant change regarding the level of serum bone metabolic markersβ-CTx,NMID,andβ-Crosslaps,which is of great value in the diagnosis,assessment,and prognosis prediction of the disease.

关 键 词：骨代谢标志物 卵巢癌 骨转移 临床意义 

分 类 号：R737.31[医药卫生—肿瘤]